Eupraxia Pharmaceuticals Stock Gross Profit
| EPRXFDelisted Stock | USD 2.79 0.04 1.45% |
Eupraxia Pharmaceuticals fundamentals help investors to digest information that contributes to Eupraxia Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Eupraxia Pink Sheet. The fundamental analysis module provides a way to measure Eupraxia Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Eupraxia Pharmaceuticals pink sheet.
Eupraxia |
Eupraxia Pharmaceuticals Company Gross Profit Analysis
Eupraxia Pharmaceuticals' Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
CompetitionAccording to the company disclosure, Eupraxia Pharmaceuticals reported 0.0 of gross profit. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The gross profit for all United States stocks is 100.0% higher than that of the company.
Eupraxia Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eupraxia Pharmaceuticals' direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Eupraxia Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Eupraxia Pharmaceuticals by comparing valuation metrics of similar companies.Eupraxia Pharmaceuticals is currently under evaluation in gross profit category among its peers.
Eupraxia Fundamentals
| Return On Equity | -0.89 | |||
| Return On Asset | -0.33 | |||
| Current Valuation | 43.78 M | |||
| Shares Outstanding | 21.39 M | |||
| Shares Owned By Insiders | 12.40 % | |||
| Shares Owned By Institutions | 20.24 % | |||
| Price To Book | 3.89 X | |||
| EBITDA | (21.96 M) | |||
| Net Income | (22.99 M) | |||
| Cash And Equivalents | 35.46 M | |||
| Cash Per Share | 1.66 X | |||
| Total Debt | 9.26 M | |||
| Debt To Equity | 0.42 % | |||
| Current Ratio | 10.13 X | |||
| Book Value Per Share | 0.95 X | |||
| Cash Flow From Operations | (14.64 M) | |||
| Earnings Per Share | (0.98) X | |||
| Number Of Employees | 19 | |||
| Market Capitalization | 78.89 M | |||
| Total Asset | 31.22 M | |||
| Z Score | 4.8 | |||
| Net Asset | 31.22 M |
About Eupraxia Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Eupraxia Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eupraxia Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eupraxia Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| EBR | Centrais Electricas Brasileiras | |
| HE | Hawaiian Electric Industries | |
| VFC | VF Corporation | |
| BVHMF | Vistry Group PLC | |
| S | SentinelOne |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Other Consideration for investing in Eupraxia Pink Sheet
If you are still planning to invest in Eupraxia Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eupraxia Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |